Arthur M. Krieg - 16 Jun 2021 Form 4 Insider Report for Checkmate Pharmaceuticals, Inc.

Role: Chief Scientific Officer
Signature: /s/ Katherine Eade, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 16 Jun 2021
Net transactions value: +$22,112
Form type: 4
Filing time: 17 Jun 2021, 16:33:25 UTC
Previous filing: 01 Jun 2021
Next filing: 21 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CMPI	Common Stock	Purchase	$22,112	+3,578	+0.44%	$6.18	808,510	16 Jun 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions, at prices ranging from $6.17 to $6.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Content

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions, at prices ranging from $6.17 to $6.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

Exhibit 24 - Power of Attorney